Send to

Choose Destination
See comment in PubMed Commons below
Leuk Res. 2012 Jun;36(6):664-71. doi: 10.1016/j.leukres.2012.02.027. Epub 2012 Mar 28.

Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques.

Author information

  • 1Mayo Clinic, Scottsdale, AZ 85259, United States.


The efficacy of tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) has brought treatment response assessment to the molecular level. Clinical trials endpoints for newer TKIs - such as major and complete molecular response - reflect the trend toward more-sensitive disease detection and deeper responses. Practice guidelines now formally define levels of response and link response benchmarks to outcome and treatment guidance. Efforts are ongoing to harmonize the methodology and terminology used to characterize molecular response. This review discusses the evolution of CML clinical trial endpoints in response to current therapeutic and monitoring modalities, and the implications of achieving molecular endpoints.

Copyright © 2012 Elsevier Ltd. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk